EN
Sinovac Foundation Donates Poliomyelitis Vaccines to Bangladesh
DHAKA, Bangladesh, May 13, 2026 — Sinovac Foundation has donated 76,616 vials (383,080 doses) of SINOVAC’s Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (sIPV) to bolster Bangladesh’s polio eradication efforts.
Photo Credit: Press Information Department (PID), Bangladesh.
The official handover ceremony was held at the conference room of the Bangladesh Secretariat in Dhaka. During the ceremony, Li Ning, representing Sinovac Foundation, formally handed over the vaccine donation to Sardar Md. Sakhawat Husain, Minister for Health and Family Welfare of Bangladesh.
Photo Caption: Mr. Sardar Md. Sakhawat Husain, Honorable Minister for Health and Family Welfare of the Government of the People’s Republic of Bangladesh, receives a symbolic token of the donated vaccine during a ceremony held at the Bangladesh Secretariat in Dhaka on May 13, 2026. Photo Credit: Press Information Department (PID), Bangladesh.
Minister Sardar Md. Sakhawat Husain expressed sincere gratitude to Sinovac Foundation for the timely humanitarian support. He commented that the WHO-prequalified sIPV would effectively reinforce Bangladesh's Expanded Programme on Immunization (EPI), improve pediatric vaccination coverage in remote areas, and strengthen the country's national polio prevention capacity.
Li Shaopeng, Cultural Counselor of the Chinese Embassy in Dhaka, stated that this vaccine donation embodies the profound friendship between China and Bangladesh and underscores the two nations' joint commitment to public health security.
Li Ning, representing Sinovac Foundation, emphasized that vaccination is the most effective intervention against poliomyelitis. She noted that Sinovac Foundation was honored to support Bangladesh's national immunization agenda.
The ceremony was also attended by Huang Moucong, Second Secretary of the Chinese Embassy in Dhaka, as well as senior officials from Bangladesh's DGHS, EPI, DGDA and other relevant health authorities.
Moving forward, Sinovac Foundation will continue to assist in optimizing local healthcare systems and strengthen bilateral public health cooperation to advance global immunization outcomes. The Foundation will continue to expand vaccine accessibility and promote sustainable public health development across Bangladesh.
About SINOVAC Foundation
Beijing SINOVAC Foundation (hereinafter referred to as "SINOVAC Foundation") was established by SINOVAC to actively perform its social responsibilities. SINOVAC Foundation focuses on promoting the sustainable development in the biomedical field, provides vigorous support to the scientific and technological innovation in the life health field, and contributes wisdom and power to social harmony and health by funding scientific research innovation projects, promoting academic exchanges and talent cultivation, and timely responding to natural disasters, accidents, publichealth incidents and other emergencies.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.